Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Gynaecological cancers 2

LBA34 - Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

Date

18 Sep 2020

Session

Mini Oral - Gynaecological cancers 2

Presenters

David O'Malley

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

D.M. O'Malley1, A. Oaknin2, B.J. Monk3, A. Leary4, F. Selle5, J. Alexandre6, L.M. Randall7, C. Rojas8, M. Neffa9, A. Kryzhanivska10, L. Gladieff11, D. Berton12, T. Meniawy13, I. Lugowska14, I. Bondarenko15, K.N. Moore16, W.I. Ortuzar Feliu17, M. Ancukiewicz18, I. Shapiro19, I.L. Ray-Coquard20

Author affiliations

  • 1 Gynecology And Obstetrics, OSUCCC - The Ohio State University Comprehensive Cancer Center - James, 43210 - Columbus/US
  • 2 Medical Oncology, Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 3 Gynecologic Oncology Department, Arizona Oncology (US Oncology Network), 85016 - Phoenix/US
  • 4 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 5 Medical Oncology, Hôpital Croix Saint Simon – Diaconesses, 75020 - Paris/FR
  • 6 Medical Oncology, Université de Paris, hôpital Cochin, 75014 - Paris/FR
  • 7 Department Of Obstetrics And Gynecology, Massey Cancer Center, Virginia Commonwealth University, 23298 - Richmond/US
  • 8 Medical Oncology, Universidad de los Andes, 8420323 - Santiago/CL
  • 9 Department Of Surgery, CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection,, 61166 - Kharkiv/UA
  • 10 Medical Oncology, CI Transcarpathian Cl Onc Center Dep of Surgery#1 SHEI Ivano-Frankivsk NMU, 76018 - Ivano-Frankivsk/UA
  • 11 Medical Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 12 Medical Oncology, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens (GINECO), Institut de Cancérologie de l'Ouest (ICO) Centre René Gauducheau, Saint-Herblain/FR
  • 13 Medical Oncology, Linear Clinical Research, Nedlands/AU
  • 14 Medical Oncology, Maria Sklodowska-Curie Memorial Cancer Centre-Institute of Oncology, 02-781 - Warsaw/PL
  • 15 Haematology, Oncology, 4Municipal Institution City Clinical Hospital, Dnipropetrovsk Oblast/UA
  • 16 Department Of Obstetrics And Gynecology University, Stephenson Cancer Center/University of Oklahoma, 73104 - Oklahoma City/US
  • 17 Clinical Development, Agenus Inc - Corporate HQ, R&D and Vaccine Manufacturing, 2421 - Lexington/US
  • 18 Clinical Development, Agenus Inc., Lexington/US
  • 19 Global Development, agenus inc., 02421 - Lexington/US
  • 20 Medical Oncology Department, Centre Léon Bérard, 69008 - Lyon/FR
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA34

Background

Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.

Methods

Patients received single-agent bal 3mg/kg q2w (NCT03104699) or in combination with zal 1mg/kg q6w (NCT03495882) up to 2 yrs. The primary endpoint was objective response rates (ORR) assessed per RECIST 1.1 by independent review, secondary endpoints included safety and DOR.

Results

We treated161 & 155 pts in the bal and bal/zal, respectively with 160 & 143 pts had baseline measurable disease (modified ITT population). All pts previously received platinum-based treatment for their first line as per protocol. Squamous-cell cancer (SCC) (63% bal; 74% bal/zal) was the predominant histologic subtype with adenocarcinoma/adenosquamous/other (AC) also represented. PD-L1 positive was defined as CPS ≥ 1% (62% bal; 55% bal/zal), negative as CPS <1% (26% bal; 25% bal/zal) or unknown (12% bal; 20% bal/zal). Efficacy data are below.

Treatment was well tolerated in both trials. 49 (30%) pts had immune-related AEs in bal & 50 (35%) in bal/zal trial (all grades) and severe (Grade 3+) 13 (8.0%) and 15 (10.5%) respectively. Treatment discontinuation were seen in 22 pts (13.7%) in bal and 15 pts (10%) in bal/zal. There were no treatment related deaths on the bal trial and 2 in the bal/zal trial (nephritis; pneumonitis). No new safety signals were identified. Table: LBA34

Efficacy bal (160) N (%) bal/zal (143) N (%)
ORR 24 (14) 31 (22)
CR 3 (2) 8 (6)
PR 20 (12) 23 (16)
DOR (m) 15.4 [1.1+,15.4] NR [1.3+,16.6+]
SCC 18/100 (18) 28/106 (27)
AC 5/59 (8) 3/37 (7)
PD-L1 + 19/99 (19) 21/79 (27)
PD-L1 - 4/42 (10) 4/36 (11)
Unknown PD-L1 0/19 (0) 6/28 (21)

Conclusions

These results show that both single-agent bal and bal/zal are active and well tolerated in R/M CC. Adding bal to zal increased both ORR and DOR with marginal increase in AEs. Responses were more common in the PD-L1 + and SCC pts, but responses were seen in PD-L1-, AC pts. This is by far the largest reported study of checkpoint inhibitors in cervical cancer to date.

Clinical trial identification

NCT03104699, NCT03495882.

Editorial acknowledgement

Legal entity responsible for the study

Agenus Inc.

Funding

Agenus Inc.

Disclosure

D.M. O'Malley: Honoraria (institution): AstraZeneca; Research grant/Funding (self): Clovis; Honoraria (self): Tesaro; Honoraria (self), Honoraria (institution): Immunogen; Honoraria (self): Ambry; Honoraria (self), Honoraria (institution): Jansen/J&J; Honoraria (self), Honoraria (institution): AbbVie; Honoraria (self), Honoraria (institution): Regeneron; Honoraria (self), Honoraria (institution): Amgen; Honoraria (self), Honoraria (institution): Novocure; Honoraria (self), Honoraria (institution): Genentech/Roche; Honoraria (institution): VentiRx; Honoraria (institution): Array Biopharma; Research grant/Funding (institution): EMD Serono; Research grant/Funding (institution): Ergomed; Research grant/Funding (institution): Ajinomoto Inc.; Research grant/Funding (institution): Stemcentrx, Inc.; Research grant/Funding (institution): Cerulean Pharma; Honoraria (self), Research grant/Funding (institution): GOG Foundation; Research grant/Funding (institution): Bristol-Myers Squibb Co; Research grant/Funding (institution): Serono Inc; Research grant/Funding (institution): Tracon Pharmaceuticals; Research grant/Funding (institution): Yale University; Research grant/Funding (institution): New Mexico Cancer Care Alliance; Research grant/Funding (institution): INC Research, Inc; Research grant/Funding (institution): inVentiv Health Clinical; Research grant/Funding (institution): Iovance Biotherapeutics, Inc; Research grant/Funding (institution): PRA Int; Honoraria (self): Myriad Genetics; Honoraria (self), Research grant/Funding (institution): Esai. I.L. Ray-Coquard: Honoraria (self), Advisory/Consultancy: Agenus Inc.; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy: advaxis; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): BMS; Honoraria (self), Advisory/Consultancy: PharmaMar; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Genmab; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: GSK; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): MSD; Honoraria (self), Advisory/Consultancy: Deciphera; Honoraria (self), Advisory/Consultancy: Mersena; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy: Tesaro; Honoraria (self), Advisory/Consultancy: Clovis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings